Although there are numerous studies on the prognostic value of NLR in advanced melanoma and on the predictive potential of NLR in the treatment with ICI or BRAF/MEK-inhibitors, few studies analyze the prognostic potential of NLR and other blood ratios in localized melanoma stages, especially in patients who did not receive adjuvant ICI or targeted therapy. Here, BRAF is linked to melanoma.